Park Medi World Q1: consolidated PAT ₹88.6 Cr up 35% YoY as new hospitals scale

Park Medi World's first standalone-listed quarter (IPO Dec-2025) shows the consolidated engine firing on capacity additions: revenue from operations of ₹475.7 Cr grew 19.3% YoY (a softer +3.3% QoQ), and consolidated PAT of ₹88.6 Cr rose 35.2% YoY, with the parent's share at ₹82.5 Cr (EPS ₹2.05 vs ₹1.70 a year ago). Crucially, pre-tax profit of ₹105.1 Cr was up 28.3% YoY, so the earnings growth is operational rather than accounting — but the eye-catching +15% QoQ PAT is largely a tax effect: the effective tax rate fell to 15.7% (a ₹9.3 Cr deferred-tax benefit) from 25.7% in Q4, while PBT was essentially flat sequentially. The standalone entity is just a small holding company (revenue ₹33.5 Cr, PAT ₹1.1 Cr); the consolidated figures are the real business.

On margins, net profit margin expanded to ~18.6% (from ~16.7% QoQ) but operating margin eased to ~26.5% from 27.7% in Q4 — a mild compression consistent with newly commissioned units (Panchkula, 350 beds, live Apr-10; Rudrapur, 330 beds, launched Aug-2) absorbing ramp-up costs before hitting steady-state utilisation. This directly tests management's prior-call guidance that new hospitals would ramp "without diluting margins"; the YoY margin picture holds, but the sequential OPM dip is the line to watch. There is no published street consensus for this recently-listed name — coverage is thin — though the stock rose ~5% into the print on positioning.

The stock went into the print at ₹295.8, up 0.3% over the past month of trading.

The quarter's board actions reinforce the expansion thesis management has been selling. Alongside results, the board approved the all-cash ₹107 Cr acquisition of Mehar Hospital, Zirakpur (150+ beds), densifying the Tricity cluster; this follows the ₹177 Cr Medicity/Rudrapur deal and Panchkula commissioning. Management now guides total capacity to ~5,800 beds by March 2028 — an upward revision from the ~5,460 flagged on the Q4 call — after adding ~1,500 beds (~46%) in twelve months, framing the print as "pace and prudence" with acquisitions structured to be earnings-accretive. Funding leans on internal accruals plus unutilised IPO proceeds (₹648 Cr pending as on June-30). The near-term question is whether the CGHS-linked 5-6% revenue tailwind management guided for FY27 and improving utilisation at the new units lift OPM back toward 27-28% as the added beds mature.